Zoledronic acid
- Generic Name
- Zoledronic acid
- Brand Names
- Aclasta, Reclast, Zometa, Zoledronic Acid Accord, Zoledronic acid Actavis, Zoledronic acid medac, Zoledronic acid Teva, Zoledronic Acid Hospira, Zoledronic acid Mylan
- Drug Type
- Small Molecule
- Chemical Formula
- C5H10N2O7P2
- CAS Number
- 118072-93-8
- Unique Ingredient Identifier
- 70HZ18PH24
- Background
Zoledronic acid, or CGP 42'446, is a third generation, nitrogen containing bisphosphonate similar to ibandronic acid, minodronic acid, and risedronic acid. Zoledronic acid is used to treat and prevent multiple forms of osteoporosis, hypercalcemia of malignancy, multiple myeloma, bone metastases from solid tumors, and Paget’s disease of bone. Zoledronic acid was first described in the literature in 1994.
Zoledronic acid was granted FDA approval on 20 August 2001.
- Indication
Zoledronic acid is indicated to treat hypercalcemia of malignancy, multiple myeloma, bone metastases from solid tumors, osteoporosis in men and postmenopausal women, glucocorticoid induced osteoporosis, and Paget's disease of bone in men and women. Zoledronic acid is also indicated for the prevention of osteoporosis in post menopausal women and glucocorticoid induced osteoporosis.
- Associated Conditions
- Bone Metastases, Hypercalcemia of Malignancy, Multiple Myeloma (MM), Osteoporosis, Osteoporosis caused by Glucocorticoid Treatment, Paget's Disease of Bone, Paget’s Disease
- Associated Therapies
- Bone Mineral Density
Intravenous Zoledronic Acid for the Treatment of Osteoporosis and Osteonecrosis in Children With Leukemia: A Pilot Study
- Conditions
- OsteonecrosisAcute Lymphoblastic LeukemiaOsteoporosis
- Interventions
- First Posted Date
- 2015-12-17
- Last Posted Date
- 2018-08-22
- Lead Sponsor
- Children's Hospital of Eastern Ontario
- Registration Number
- NCT02632903
- Locations
- 🇨🇦
Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada
Preventive Effects of Zoledronic Acid on Bone Metastasis in Patients With Stage IIIB and IV Lung Cancer
- First Posted Date
- 2015-12-04
- Last Posted Date
- 2017-07-21
- Lead Sponsor
- Tang-Du Hospital
- Target Recruit Count
- 200
- Registration Number
- NCT02622607
- Locations
- 🇨🇳
Department of Oncology，Tangdu Hospital，Fourth Millitary Medical University, XI'an, Shaanxi, China
Zoledronic Acid as Adjuvant Treatment of Triple-negative Breast Cancer
- First Posted Date
- 2015-11-03
- Last Posted Date
- 2015-11-03
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 430
- Registration Number
- NCT02595138
Zoledronic Acid for Osteoporotic Fracture Prevention (ZEST II)
- Conditions
- Osteoporotic FracturesOsteoporosis, Postmenopausal
- Interventions
- First Posted Date
- 2015-10-28
- Last Posted Date
- 2023-09-26
- Lead Sponsor
- Susan L. Greenspan
- Target Recruit Count
- 310
- Registration Number
- NCT02589600
- Locations
- 🇺🇸
University of Pittsburgh Osteoporosis Prevention & Treatment Center, New Kensington, Pennsylvania, United States
Ixazomib Citrate, Lenalidomide, Dexamethasone, and Zoledronic Acid or Zoledronic Acid Alone After Radiation Therapy in Treating Patients With Solitary Plasmacytoma of Bone
- Conditions
- Solitary Osseous Plasmacytoma
- Interventions
- First Posted Date
- 2015-08-05
- Last Posted Date
- 2021-08-17
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 11
- Registration Number
- NCT02516423
- Locations
- 🇺🇸
Saint Luke's Mountain States Tumor Institute - Nampa, Nampa, Idaho, United States
🇺🇸Illinois CancerCare-Carthage, Carthage, Illinois, United States
🇺🇸Illinois CancerCare-Galesburg, Galesburg, Illinois, United States
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- Conditions
- Acute Myeloid LeukemiaRhabdomyosarcomaAcute Lymphoblastic LeukemiaNeuroblastomaHodgkin LymphomaNon-Hodgkin LymphomaMyelodysplastic SyndromeMyeloproliferative SyndromeEwing SarcomaPrimitive Neuroectodermal Tumor
- Interventions
- Procedure: TCRαβ+/CD19+ depleted Haploidentical HSCT
- First Posted Date
- 2015-07-24
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- University of Wisconsin, Madison
- Target Recruit Count
- 22
- Registration Number
- NCT02508038
- Locations
- 🇺🇸
University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States
Zoledronic Acid to Maintain Bone Mass After Denosumab Discontinuation
- Conditions
- Postmenopausal Osteoporosis
- Interventions
- First Posted Date
- 2015-07-16
- Last Posted Date
- 2019-03-11
- Lead Sponsor
- 424 General Military Hospital
- Target Recruit Count
- 57
- Registration Number
- NCT02499237
- Locations
- 🇬🇷
251 Airforce & VA General Hospital, Athens, Greece
🇬🇷424 General Military Hospital, Thessaloniki, Greece
Zoledronic Acid Combined Radiotherapy for Bone Metastasis of Non-small Cell Lung Cancer
- Conditions
- Non-small Cell Lung CancerBone Metastasis
- Interventions
- Radiation: Radiotherapy
- First Posted Date
- 2015-06-24
- Last Posted Date
- 2019-01-16
- Lead Sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
- Target Recruit Count
- 280
- Registration Number
- NCT02480634
Pilot Trial of Zoledronic Acid to Prevent Bone Loss in Hematopoietic Cell Transplant Recipients
- Conditions
- Hematopoietic Stem Cell TransplantBone Marrow Transplant
- Interventions
- First Posted Date
- 2015-05-22
- Last Posted Date
- 2017-07-28
- Lead Sponsor
- Stanford University
- Registration Number
- NCT02451462
Pre-operative Zoledronate in Triple Negative Breast Cancer
- First Posted Date
- 2015-01-27
- Last Posted Date
- 2018-11-06
- Lead Sponsor
- Mario Negri Institute for Pharmacological Research
- Target Recruit Count
- 22
- Registration Number
- NCT02347163
- Locations
- 🇮🇹
Oncologia 2 Istituto Oncologico Veneto IRCCS, Padova, Italy
🇮🇹Azienda Ospedaliera Spedali Civili di Brescia, Brescia, BS, Italy
🇮🇹Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.